Genesis Molecular AI
4 known investors
Genesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.
AI & Machine LearningBiotech
Investors · 4
In the news
- Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration | PharmExecpharmexec.com · 2026
- Incyte-Genesis expands AI drug discovery deal with $120M funding and new targets | Seeking Alphaseekingalpha.com · 2026
- Genesis Molecular AI Unveils Pearl, a Field-Leading Foundation Model that Achieves Unprecedented Performance in Drug-Protein Structure Predictionfinance.yahoo.com · 2025
- Genesis Molecular AI - Propagator Venturespropagator.vc · 2024